Clene (CLNN) 8-K Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022

Improvement of Brain Energy Metabolism in Relapsing MS Results from Phase 2 REPAIR-MS Clinical Trial With CNM-Au8 P100 Robert Glanzman1, Jimin Ren2, Austin Rynders1, Karen S. Ho1, Michael T. Hotchkin1 Benjamin Greenberg2 1Clene Nanomedicine, Inc. Holladay, UT/United States of America, 2UT Southwestern. Dallas, TX/United States of America Design: Open-label, dose blinded 12-week treatment (n=13) Safety: No SAEs; TEAEs were all mild-to-moderate severity and transient Results: Statistically significant increase in NAD+/NADH ratio based on pre-specified integrated analyses of PD & MS cohorts MS population trend in brain NAD+/NADH ratio improvement driven by increased NAD+ and decreased NADH CNM-Au8 treatment equilibrated key markers of brain metabolism Demonstration of CNS target engagement Primary Endpoint Post-Treatment Washout Returned NAD+/NADH to Baseline Levels Improved Key Indices of Energetic Potential Improved NAD+/NADH Ratio